



BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
---------------------	-------------------	-------------------------	--------------------------

Lupin Launches Generic Combivir® Tablets

Mumbai / Baltimore, May 15, 2012: Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Lamivudine and Zidovudine Tablets, 150 mg/300 mg. from the United States Food and Drugs Administration (FDA). Lupin has already commenced shipping the product.

Lupin's Lamivudine and Zidovudine Tablets are the AB-rated generic equivalent of Viiv Healthcare's Combivir® Tablets, 150 mg/300 mg. Combivir® Tablets, 150 mg/300 mg had annual U.S sales of approximately US\$ 275 million for the twelve months ending December 2011 (IMS Health sales data)

Lamivudine - Zidovudine is a combination of two nucleoside analogue reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infective and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated Revenues and Profit after Tax were Rs.70,829 Million and Rs. 8,676 Million respectively. Please visit <http://www.lupinworld.com> for more information on Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

For further information or queries, please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com or

Rajiv Pillai
Head – Investor Relations
Lupin Limited:

Ph: +91 98 20 552 083

Email: rajivpillai@lupinpharma.com

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release

** Combivir® tablets are a registered copyright / trademark of VüV Healthcare.*